343 related articles for article (PubMed ID: 20460347)
21. Neutralization of DHG, a new depolymerized holothurian glycosaminoglycan, by protamine sulfate and platelet factor 4.
Sasaki E; Minamiguchi K; Kitazato KT; Nagase H; Kitazato K
Haemostasis; 1997; 27(4):174-83. PubMed ID: 9483172
[TBL] [Abstract][Full Text] [Related]
22. Heparin and low molecular weight heparin in thrombosis and beyond.
Mousa SA
Curr Opin Investig Drugs; 2002 Aug; 3(8):1181-6. PubMed ID: 12211411
[TBL] [Abstract][Full Text] [Related]
23. Comparison of the hemodynamic and hematologic toxicity of a protamine variant after reversal of low-molecular-weight heparin anticoagulation in a canine model.
Hulin MS; Wakefield TW; Andrews PC; Wrobleski SK; Kadell AM; Downing LJ; Stanley JC
Lab Anim Sci; 1997 Apr; 47(2):153-60. PubMed ID: 9150494
[TBL] [Abstract][Full Text] [Related]
24. Chemical and pharmacological aspects of neutralization of heparins from different animal sources by protamine.
Glauser BF; Santos GRC; Silva JD; Tovar AMF; Pereira MS; Vilanova E; Mourão PAS
J Thromb Haemost; 2018 Sep; 16(9):1789-1799. PubMed ID: 29968421
[TBL] [Abstract][Full Text] [Related]
25. Reversal of low-molecular-weight heparin anticoagulation by synthetic protamine analogues.
Wakefield TW; Andrews PC; Wrobleski SK; Kadell AM; Fazzalari A; Nichol BJ; Vanderkooi T; Stanley JC
J Surg Res; 1994 Jun; 56(6):586-93. PubMed ID: 8015315
[TBL] [Abstract][Full Text] [Related]
26. Low molecular weight heparins prevent thrombin-induced thrombo-embolism in mice despite low anti-thrombin activity. Evidence that the inhibition of feed-back activation of thrombin generation confers safety advantages over direct thrombin inhibition.
Momi S; Nasimi M; Colucci M; Nenci GG; Gresele P
Haematologica; 2001 Mar; 86(3):297-302. PubMed ID: 11255277
[TBL] [Abstract][Full Text] [Related]
27. Experimental studies on the antithrombotic and haemorrhagic effects of heparin and a low molecular weight heparin derivative.
Kaiser B; Hauptmann J; Markwardt F
Folia Haematol Int Mag Klin Morphol Blutforsch; 1988; 115(1-2):119-25. PubMed ID: 2459005
[TBL] [Abstract][Full Text] [Related]
28. Interactions of oversulfated chondroitin sulfate (OSCS) from different sources with unfractionated heparin.
Gray A; Litinas E; Jeske W; Fareed J; Hoppensteadt D
Clin Appl Thromb Hemost; 2012; 18(2):166-73. PubMed ID: 22311630
[TBL] [Abstract][Full Text] [Related]
29. Comparative human pharmacology of low molecular weight heparins.
Harenberg J; Stehle G; Augustin J; Zimmermann R
Semin Thromb Hemost; 1989 Oct; 15(4):414-23. PubMed ID: 2554502
[TBL] [Abstract][Full Text] [Related]
30. Biochemical and pharmacologic profile of low molecular weight heparin (LU 47311, Clivarin).
Jeske W; Lojewski B; Walenga JM; Hoppensteadt D; Ahsan A; Fareed J
Semin Thromb Hemost; 1993; 19 Suppl 1():229-40. PubMed ID: 8395727
[TBL] [Abstract][Full Text] [Related]
31. [Therapeutic indications of low molecular weight heparins].
Samama MM; Michaut-Paterno F
Arch Mal Coeur Vaiss; 1991 Nov; 84(11 Suppl):1733-43. PubMed ID: 1662941
[TBL] [Abstract][Full Text] [Related]
32. [Anticoagulant activity of low-molecular-weight heparins obtained using a hydrolase complex].
Drozd NN; Tolstenkov AS; Bannikova GE; Miftakhova NT; Lapikova ES; Makarov VA; Varlamov VP
Eksp Klin Farmakol; 2007; 70(6):19-24. PubMed ID: 18318190
[TBL] [Abstract][Full Text] [Related]
33. Are the available low-molecular-weight heparin preparations the same?
Fareed J; Jeske W; Hoppensteadt D; Clarizio R; Walenga JM
Semin Thromb Hemost; 1996; 22 Suppl 1():77-91. PubMed ID: 8807734
[TBL] [Abstract][Full Text] [Related]
34. Cationic derivative of dextran reverses anticoagulant activity of unfractionated heparin in animal models of arterial and venous thrombosis.
Kalaska B; Sokolowska E; Kaminski K; Szczubialka K; Kramkowski K; Mogielnicki A; Nowakowska M; Buczko W
Eur J Pharmacol; 2012 Jul; 686(1-3):81-9. PubMed ID: 22579410
[TBL] [Abstract][Full Text] [Related]
35. [Antithrombotic properties of heparin independent of its anticoagulant activity].
Krupiński K; Bielawiec M; Breddin HK
Acta Haematol Pol; 1994; 25(3):243-51. PubMed ID: 7992597
[TBL] [Abstract][Full Text] [Related]
36. Partial reversal of low molecular weight heparin (PK 10169) anti-Xa activity by protamine sulfate: in vitro and in vivo study during cardiac surgery with extracorporeal circulation.
Massonnet-Castel S; Pelissier E; Bara L; Terrier E; Abry B; Guibourt P; Swanson J; Jaulmes B; Carpentier A; Samama M
Haemostasis; 1986; 16(2):139-46. PubMed ID: 3710291
[TBL] [Abstract][Full Text] [Related]
37. Low-molecular-weight heparin in the treatment of deep venous thrombosis.
Hauer KE
West J Med; 1998 Oct; 169(4):240-4. PubMed ID: 9795594
[TBL] [Abstract][Full Text] [Related]
38. Prolonged bleeding time induced by anticoagulant glycosaminoglycans in dogs is associated with the inhibition of thrombin-induced platelet aggregation.
Kitazato K; Kitazato KT; Sasaki E; Minamiguchi K; Nagase H
Thromb Res; 2003; 112(1-2):83-91. PubMed ID: 15013278
[TBL] [Abstract][Full Text] [Related]
39. A [+18RGD] protamine variant for nontoxic and effective reversal of conventional heparin and low-molecular-weight heparin anticoagulation.
Wakefield TW; Andrews PC; Wrobleski SK; Kadell AM; Tejwani S; Hulin MS; Stanley JC
J Surg Res; 1996 Jun; 63(1):280-6. PubMed ID: 8661211
[TBL] [Abstract][Full Text] [Related]
40. In vitro studies on the biochemistry and pharmacology of low molecular weight heparins.
Jeske W; Fareed J
Semin Thromb Hemost; 1999; 25 Suppl 3():27-33. PubMed ID: 10549713
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
